Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
+$0.45 today
- Market cap
- $53.90M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
Volume 0.01M
Average 0.05M
XLO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Xilio Therapeutics, Inc.NASDAQ: XLO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $6.58M fell 22.7% year over year, behind the +2.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 11.0% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Selling, general & admin amounted to 67.9% of revenue in FY2025, down 322.7 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $64.72M (+117.8%) for the fiscal year ending Dec 2026, a step up from the +19.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.58M-11.0% QoQ
- Last fiscal yearDec 2025
- $29.71M+19.9% YoY
- LTMMar 2026
- $27.78M+2.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 29.71M USD
- Year-over-year change
- +19.9%
- 4-year CAGR
- +7.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.71M | +19.9% |
| FY2024 | 2024-12-31 | 24.78M | -8.2% |
| FY2023 | 2023-12-31 | 27M | -9.9% |
| FY2022 | 2022-12-31 | 29.95M | +34.0% |
| FY2021 | 2021-12-31 | 22.36M | — |
Selling, General & Admin vs competitors
How XLO compares with its peers on the latest reported figures
- XLO's LTM Mar 2026 selling, general & admin of $27.78M is the 2nd highest of the 4 companies compared; the peer median is $14.61M.
- Its year-over-year change of +2.3% is the 3rd highest of 4, against a peer median of +87.7%.
- Selling, general & admin amounts to 51.9% of revenue for XLO, versus a peer median of 21.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.07B | +22461.6% | +0.7% | — | |
| LTM Mar 2026 | $27.78M | +2.3% | -0.3% | 51.9% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $14.61M | +87.7% | +55.5% | — |
| LTM Jun 2026 | $7.41M | -56.6% | +8.2% | 21.1% | |
| Peer median (excluding XLO) | $14.61M | +87.7% | +8.2% | 21.1% | |
Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 6.34M | 43.77M |
| Cost of Revenue | 1.5M | 0 | 0 | 0 | 1.54M |
| Gross Profit | (1.5M) | 0 | 0 | 6.34M | 42.23M |
| Gross Margin | — | — | — | 100.0% | 96.5% |
| Research & Development | 51.19M | 59.2M | 52.14M | 41.21M | 56.04M |
| Selling, General & Admin | 22.36M | 29.95M | 27M | 24.78M | 29.71M |
| Operating Expenses | 73.55M | 89.15M | 79.13M | 66.93M | 84.21M |
| Depreciation & Amortization | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| EBITDA | (73.7M) | (86.38M) | (74.5M) | (58M) | (33.5M) |
| EBITDA Margin | — | — | — | -914.3% | -76.5% |
| Operating Income | (75.04M) | (89.15M) | (79.13M) | (60.58M) | (41.98M) |
| Operating Margin | — | — | — | -954.9% | -95.9% |
| Interest Income | 600 | 0 | 0 | 0 | 3.4M |
| Interest Expense | 600K | 0 | 0 | 100K | 0 |
| Other Income / Expenses | (756K) | 927K | 2.73M | 2.34M | 6.95M |
| Income Before Tax | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Pre-Tax Margin | — | — | — | -918.0% | -80.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Net Margin | — | — | — | -918.0% | -80.1% |
| EPS (Basic) | (189.28) | (45.08) | (38.92) | (15.26) | (4.19) |
| EPS (Diluted) | (189.28) | (45.08) | (38.92) | (15.26) | (4.19) |
| Weighted Avg Shares | 400.45K | 1.96M | 1.96M | 3.82M | 83.59M |
| Weighted Avg Shares (Diluted) | 400.45K | 1.96M | 1.96M | 3.82M | 83.59M |
Xilio Therapeutics, Inc.
NASDAQ:XLO
Intrinsic Alpha fair value
Locked
Current Price
$7.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.